Fingolimod significantly reduced brain volume loss in patients with relapsing-remitting multiple sclerosis: 4-year data from FREEDOMS extension study

被引：0
|
作者：
Radue, E.
Kappos, L.
O'Connor, P.
Polman, C.
Hohlfeld, R.
Calabresi, P.
Selmaj, K.
de Vera, A.
Sfikas, N.
Zhang-Auberson, L.
Francis, G.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[3] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[4] Univ Munich, Munich, Germany
[5] Johns Hopkins Multiple Sclerosis Ctr, Baltimore, MD USA
[6] Med Acad Lodz, Lodz, Poland
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [31] Immunogenicity with peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the randomised phase 3, multicentre ADVANCE study in relapsing-remitting multiple sclerosis
    White, J. T.
    Kieseier, B. C.
    Newsome, S. D.
    Zhu, Y.
    Cui, Y.
    Seddighzadeh, A.
    Hung, S.
    Deykin, A.
    Subramanyam, M.
    JOURNAL OF NEUROLOGY, 2014, 261 : S234 - S234
  • [32] Immunogenicity with peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the randomised phase 3, multicentre ADVANCE study in relapsing-remitting multiple sclerosis
    White, J. T.
    Kieseier, B. C.
    Newsome, S. D.
    Zhu, Y.
    Cui, Y.
    Seddighzadeh, A.
    Hung, S.
    Deykin, A.
    Subramanyam, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 346 - 346
  • [33] The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
    Izquierdo, Guillermo
    Damas, Fatima
    Dolores Paramo, Maria
    Luis Ruiz-Pena, Juan
    Navarro, Guillermo
    PLOS ONE, 2017, 12 (04):
  • [34] Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
    Doosti, Rozita
    Moghadasi, Abdorreza Naser
    Azimi, Amir Reza
    Saleh, Shahrokh Karbalai
    Etemadifar, Masoud
    Shaygannejad, Vahid
    Ashtari, Fereshteh
    Harirchian, Mohammad Hossein
    Siroos, Seyed Bahaadin
    Ayramloo, Hormoz
    Majdinasab, Nastaran
    Hojjati, Seyyed Mohammad Masood
    Asghari, Nabiollah
    Baghbanian, Seyed Mohammad
    Cheraghmakani, Hamed
    Abedini, Mahmoud
    Sedighi, Behnaz
    Abadi, Negar Mohseni Abbas
    Ghasemitabar, Maedeh
    Talebianpour, Sara
    Daylari, Tohid Babayi
    Dana, Vahid
    Noie, Neda Ghaleh
    Sahraian, Mohammad Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2021, 12 (03) : 263 - 274
  • [35] Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
    Comi, Giancarlo
    Pozzilli, Carlo
    Morra, Vincenzo Brescia
    Bertolotto, Antonio
    Sangalli, Francesca
    Prosperini, Luca
    Carotenuto, Antonio
    Iaffaldano, Pietro
    Capobianco, Marco
    Colombo, Delia
    Nica, Mihaela
    Rizzoli, Sara
    Trojano, Maria
    NEUROLOGICAL SCIENCES, 2020, 41 (10) : 2843 - 2851
  • [36] Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
    Giancarlo Comi
    Carlo Pozzilli
    Vincenzo Brescia Morra
    Antonio Bertolotto
    Francesca Sangalli
    Luca Prosperini
    Antonio Carotenuto
    Pietro Iaffaldano
    Marco Capobianco
    Delia Colombo
    Mihaela Nica
    Sara Rizzoli
    Maria Trojano
    Neurological Sciences, 2020, 41 : 2843 - 2851
  • [37] OCT Analysis in Patients with Relapsing-Remitting Multiple Sclerosis during Fingolimod Therapy: 2-Year Longitudinal Retrospective Study
    Rossi, Settimio
    Gesualdo, Carlo
    Gallo, Antonio
    Melillo, Paolo
    Martines, Francesco
    Colucci, Raffaella
    D'Ambrosio, Alessandro
    Tedeschi, Gioacchino
    Simonelli, Francesca
    APPLIED SCIENCES-BASEL, 2020, 10 (20): : 1 - 9
  • [38] Natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis: a prospective observational study of 197 patients
    Baroncini, D.
    Ghezzi, A.
    Stefanin, C.
    Zaffaroni, M.
    Annovazzi, P.
    Baldini, S.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 191 - 192
  • [39] Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis:. case series
    Notas, Konstantinos
    Papadaki, Efrosini
    Orologas, Anastasios
    Moschou, Maria
    Kimiskidis, Vasilios K.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 38
  • [40] Effect of early switch to fingolimod from other oral therapies in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Silva, D.
    Medin, J.
    Cornelissen, C.
    Ringwald, K.
    Cohan, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 404 - 405
12345